glp-1 weight loss drugs Rx Trends: Real-World Data on GLP-1s for Half of GLP-1 users ditch
Description
10.1371/journal.pone.0097554 38 KristensenS
End Use Insights The hospitals segment held the largest market share in 2025
Published online May 2024
These data are consistent with the failure of GLP-1 to inhibit gastric acid secretion in vagotomized human subjects [807] as well as the failure of GLP-1 to inhibit vagally-induced motility in the isolated perfused pig antrum [800]
The TRIUMPH programme's 80-week and beyond data will begin to address this
Absolute risks are relatively low, but worth understanding before starting, especially for lifelong use
:max_bytes(150000):strip_icc()/Wegovy-pill-pic-590ed53ed3304ba8b2388f9d78886dae.png)
